Pioglitazone (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Pioglitazone" in Italian language version.

refsWebsite

Global rank Italian rank

14doi.org

2^nd place

7^th place

13nih.gov

4^th place

9^th place

5oadoi.org

799^th place

22^nd place

2springer.com

274^th place

393^rd place

2europa.eu

68^th place

57^th place

1drugs.com

399^th place

1,563^rd place

1diabetesjournals.org

low place

1ama-assn.org

3,257^th place

5,565^th place

1torrinomedica.it

low place

2,002^nd place

1jamanetwork.com

2,650^th place

2,089^th place

1fda.gov

447^th place

644^th place

1web.archive.org

1^st place

ama-assn.org

jama.ama-assn.org

Nissen SE, Nicholls SJ, Wolski K, et al., Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial, in JAMA, vol. 299, n. 13, aprile 2008, pp. 1561–73, DOI:10.1001/jama.299.13.1561, PMID 18378631.

diabetesjournals.org

care.diabetesjournals.org

Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A, The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients, in Diabetes Care, vol. 27, n. 7, luglio 2004, pp. 1647–53, DOI:10.2337/diacare.27.7.1647, PMID 15220241.

doi.org

dx.doi.org

British National Formulary, 10 novembre 2015, DOI:10.18578/bnf.147942626. URL consultato il 19 dicembre 2019.
Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A, The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients, in Diabetes Care, vol. 27, n. 7, luglio 2004, pp. 1647–53, DOI:10.2337/diacare.27.7.1647, PMID 15220241.
Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N, Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials, in Diabetes Obes Metab, vol. 0, maggio 2008, p. 080526191604039, DOI:10.1111/j.1463-1326.2008.00892.x, PMID 18505403.
Nissen SE, Nicholls SJ, Wolski K, et al., Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial, in JAMA, vol. 299, n. 13, aprile 2008, pp. 1561–73, DOI:10.1001/jama.299.13.1561, PMID 18378631.
(EN) Choi JS, Burm JP, Effect of pioglitazone on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rats (abstract), in Arch Pharm Res, vol. 9, n. 31, settembre 2008, pp. 1200-4, DOI:10.1007/s12272-001-1289-z, PMID 18806964.
Zhu ZN, Jiang YF, Ding T., Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials, in Bone, n. 68, novembre 2014, pp. 115-23, DOI:10.1016/j.bone.2014.08.010, PMID 25173606.
Catherine M. Viscoli, Silvio E. Inzucchi e Lawrence H. Young, Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial, in The Journal of Clinical Endocrinology and Metabolism, vol. 102, n. 3, 9 dicembre 2016, pp. 914–922, DOI:10.1210/jc.2016-3237. URL consultato il 19 dicembre 2019.
Meng Lee, Jeffrey L. Saver e Hung-Wei Liao, Pioglitazone for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis, in Stroke, vol. 48, n. 2, 2017-02, pp. 388–393, DOI:10.1161/STROKEAHA.116.013977. URL consultato il 18 gennaio 2022.
(EN) A. Michael Lincoff, Kathy Wolski e Stephen J. Nicholls, Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Trials, in JAMA, vol. 298, n. 10, 12 settembre 2007, pp. 1180–1188, DOI:10.1001/jama.298.10.1180. URL consultato il 19 dicembre 2019.
Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP Jr, Vaughn DJ, Nessel L, Selby J, Strom BL, Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study, in Diabetes Care, vol. 4, n. 34, Aprile 2011, pp. 916-22, DOI:10.2337/dc10-1068, PMID 21447663.
Ferwana M, Firwana B, Hasan R, Al-Mallah MH, Kim S, Montori VM, Murad MH., Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies, in Diabet Med, vol. 9, n. 30, Settembre 2013, pp. 1026-32, DOI:10.1111/dme.12144, PMID 23350856.
Elena Filipova, Katya Uzunova e Krassimir Kalinov, Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis, in Diabetes Therapy, vol. 8, n. 4, 2017-8, pp. 705–726, DOI:10.1007/s13300-017-0273-4. URL consultato il 19 dicembre 2019.
Lewis JD, Habel LA, Quesenberry CP, Strom BL, Peng T, Hedderson MM, Ehrlich SF, Mamtani R, Bilker W, Vaughn DJ, Nessel L, Van Den Eeden SK, Ferrara A., Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes, in JAMA, vol. 3, n. 314, 21 luglio 2015, pp. 265-77, DOI:10.1001/jama.2015.7996, PMID 26197187.
James D. Lewis, Laurel A. Habel e Charles P. Quesenberry, Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes, in JAMA, vol. 314, n. 3, 21 luglio 2015, pp. 265–277, DOI:10.1001/jama.2015.7996. URL consultato il 19 dicembre 2019.

drugs.com

(EN) Pioglitazone Hydrochloride Monograph for Professionals, su Drugs.com. URL consultato il 19 dicembre 2019.

europa.eu

ec.europa.eu

Scheda tecnica del farmaco Competact (PDF), su ec.europa.eu. URL consultato il 5 febbraio 2016.

ema.europa.eu

Dichiarazione dell'EMA su io pioglitazone e rischio di carcinoma della vescica, su ema.europa.eu. URL consultato il 12 febbraio 2016.

fda.gov

(EN) Center for Drug Evaluation and Research, FDA Drug Safety Communication: Updated FDA review concludes that use of type 2 diabetes medicine pioglitazone may be linked to an increased risk of bladder cancer, in FDA, 9 febbraio 2019. URL consultato il 19 dicembre 2019.

jamanetwork.com

(EN) A. Michael Lincoff, Kathy Wolski e Stephen J. Nicholls, Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Trials, in JAMA, vol. 298, n. 10, 12 settembre 2007, pp. 1180–1188, DOI:10.1001/jama.298.10.1180. URL consultato il 19 dicembre 2019.

nih.gov

ncbi.nlm.nih.gov

Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A, The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients, in Diabetes Care, vol. 27, n. 7, luglio 2004, pp. 1647–53, DOI:10.2337/diacare.27.7.1647, PMID 15220241.
Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N, Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials, in Diabetes Obes Metab, vol. 0, maggio 2008, p. 080526191604039, DOI:10.1111/j.1463-1326.2008.00892.x, PMID 18505403.
Nissen SE, Nicholls SJ, Wolski K, et al., Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial, in JAMA, vol. 299, n. 13, aprile 2008, pp. 1561–73, DOI:10.1001/jama.299.13.1561, PMID 18378631.
(EN) Scheen AJ, Pharmacokinetic interactions with thiazolidinediones (abstract), in Clin Pharmacokinet, vol. 1, n. 46, 2007, pp. 1-12, PMID 17201456.
(EN) Choi JS, Burm JP, Effect of pioglitazone on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rats (abstract), in Arch Pharm Res, vol. 9, n. 31, settembre 2008, pp. 1200-4, DOI:10.1007/s12272-001-1289-z, PMID 18806964.
Zhu ZN, Jiang YF, Ding T., Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials, in Bone, n. 68, novembre 2014, pp. 115-23, DOI:10.1016/j.bone.2014.08.010, PMID 25173606.
Catherine M. Viscoli, Silvio E. Inzucchi e Lawrence H. Young, Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial, in The Journal of Clinical Endocrinology and Metabolism, vol. 102, n. 3, 9 dicembre 2016, pp. 914–922, DOI:10.1210/jc.2016-3237. URL consultato il 19 dicembre 2019.
Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP Jr, Vaughn DJ, Nessel L, Selby J, Strom BL, Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study, in Diabetes Care, vol. 4, n. 34, Aprile 2011, pp. 916-22, DOI:10.2337/dc10-1068, PMID 21447663.
Ferwana M, Firwana B, Hasan R, Al-Mallah MH, Kim S, Montori VM, Murad MH., Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies, in Diabet Med, vol. 9, n. 30, Settembre 2013, pp. 1026-32, DOI:10.1111/dme.12144, PMID 23350856.
Elena Filipova, Katya Uzunova e Krassimir Kalinov, Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis, in Diabetes Therapy, vol. 8, n. 4, 2017-8, pp. 705–726, DOI:10.1007/s13300-017-0273-4. URL consultato il 19 dicembre 2019.
Lewis JD, Habel LA, Quesenberry CP, Strom BL, Peng T, Hedderson MM, Ehrlich SF, Mamtani R, Bilker W, Vaughn DJ, Nessel L, Van Den Eeden SK, Ferrara A., Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes, in JAMA, vol. 3, n. 314, 21 luglio 2015, pp. 265-77, DOI:10.1001/jama.2015.7996, PMID 26197187.
James D. Lewis, Laurel A. Habel e Charles P. Quesenberry, Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes, in JAMA, vol. 314, n. 3, 21 luglio 2015, pp. 265–277, DOI:10.1001/jama.2015.7996. URL consultato il 19 dicembre 2019.

pubmed.ncbi.nlm.nih.gov

Meng Lee, Jeffrey L. Saver e Hung-Wei Liao, Pioglitazone for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis, in Stroke, vol. 48, n. 2, 2017-02, pp. 388–393, DOI:10.1161/STROKEAHA.116.013977. URL consultato il 18 gennaio 2022.

oadoi.org

Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N, Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials, in Diabetes Obes Metab, vol. 0, maggio 2008, p. 080526191604039, DOI:10.1111/j.1463-1326.2008.00892.x, PMID 18505403.
Zhu ZN, Jiang YF, Ding T., Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials, in Bone, n. 68, novembre 2014, pp. 115-23, DOI:10.1016/j.bone.2014.08.010, PMID 25173606.
Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP Jr, Vaughn DJ, Nessel L, Selby J, Strom BL, Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study, in Diabetes Care, vol. 4, n. 34, Aprile 2011, pp. 916-22, DOI:10.2337/dc10-1068, PMID 21447663.
Ferwana M, Firwana B, Hasan R, Al-Mallah MH, Kim S, Montori VM, Murad MH., Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies, in Diabet Med, vol. 9, n. 30, Settembre 2013, pp. 1026-32, DOI:10.1111/dme.12144, PMID 23350856.
Lewis JD, Habel LA, Quesenberry CP, Strom BL, Peng T, Hedderson MM, Ehrlich SF, Mamtani R, Bilker W, Vaughn DJ, Nessel L, Van Den Eeden SK, Ferrara A., Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes, in JAMA, vol. 3, n. 314, 21 luglio 2015, pp. 265-77, DOI:10.1001/jama.2015.7996, PMID 26197187.

springer.com

link.springer.com

(EN) Scheen AJ, Pharmacokinetic interactions with thiazolidinediones (abstract), in Clin Pharmacokinet, vol. 1, n. 46, 2007, pp. 1-12, PMID 17201456.
(EN) Choi JS, Burm JP, Effect of pioglitazone on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rats (abstract), in Arch Pharm Res, vol. 9, n. 31, settembre 2008, pp. 1200-4, DOI:10.1007/s12272-001-1289-z, PMID 18806964.

torrinomedica.it

Scheda tecnica del farmaco Actos, Torrinomedica.it, su torrinomedica.it. URL consultato il 5 febbraio 2016.

web.archive.org

Actos. Il farmaco per il diabete, ritirato in Germania e Francia, ancora prescritto in Italia (e rimborsato) - Il Fatto Quotidiano, su web.archive.org, 17 giugno 2024. URL consultato il 17 giugno 2024 (archiviato dall'url originale il 17 giugno 2024).